Document Detail


Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes.
MedLine Citation:
PMID:  16625233     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the study was to examine an association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR)-gamma2 gene and blood pressure values assessed by 24-h ambulatory blood pressure monitoring (ABPM) in obese patients with long-lasting type II diabetes. Two hundred and fourteen obese patients (95 men and 119 women) with above 10-year history of type II diabetes were recruited for the study. In all the patients, ABPM was performed and other parameters, including age, body mass index (BMI), waist/hip ratio (WHR), haemoglobin A1c (HbA(1c)), serum lipids and creatinine were also evaluated. The Pro12Ala polymorphism was analysed by polymerase chain reaction-restriction fragment length polymorphism. Two subgroups of patients were compared: (a) Pro/Pro: homozygotic Pro/Pro (n=154) and (b) Ala: Ala allele carriers (Ala/Ala+Ala/Pro) (n=60). The studied groups were not different when age, BMI, WHR, HbA(1c), lipids, creatinine and frequency of hypertension were compared. A similar ratio of patients from both groups were treated with angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics, beta-blockers and alpha-blockers. A difference was observed in a mean 24-h (Ala: 71.9+/-8.1 vs Pro/Pro: 69.4+/-7.8 mm Hg, P=0.034) and a mean night time (Ala: 67.1+/-7.8 vs Pro/Pro: 64.5+/-8.4 mm Hg, P=0.025) diastolic blood pressure, which was significantly higher in patients with Ala variant. There was also a trend towards a higher mean daytime diastolic blood pressure in this group. It seems that the Pro12Ala variant is associated with an increased mean 24-h diastolic blood pressure in obese diabetic patients. Different reaction for antihypertensive medication depending on a variant of the PPAR-gamma2 gene should also be considered as a possible cause of the presented results.
Authors:
A Stefański; L Majkowska; A Ciechanowicz; M Frankow; K Safranow; M Parczewski; P Moleda; K Pilarska
Related Documents :
11385943 - Endogamy and variation in blood pressure levels in croatian island isolates.
14707163 - Autosomal-dominant hypertension with type e brachydactyly is caused by rearrangement on...
2581443 - Pathology of small blood vessel disease in hypertension.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-04-20
Journal Detail:
Title:  Journal of human hypertension     Volume:  20     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-23     Completed Date:  2006-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  684-92     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, Hypertension and Metabolic Diseases, Pomeranian Medical University, Szczecin, Poland. stefend@sci.pam.szczecin.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine / genetics*
Alleles
Blood Pressure
Body Mass Index
Diabetes Mellitus, Type 2 / complications,  genetics*,  physiopathology*
Female
Humans
Hypertension / complications,  genetics,  physiopathology
Male
Middle Aged
Obesity / complications,  genetics*,  physiopathology*
PPAR gamma / genetics*
Polymorphism, Genetic / genetics
Proline / genetics*
Time Factors
Chemical
Reg. No./Substance:
0/PPAR gamma; 147-85-3/Proline; 56-41-7/Alanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels in the peripheral venou...
Next Document:  Effect of pravastatin on blood pressure in people with cardiovascular disease.